EP3060220A4 - Compositions pour administration orale d'acide zolédronique ou de composés associés pour le traitement de maladies - Google Patents

Compositions pour administration orale d'acide zolédronique ou de composés associés pour le traitement de maladies Download PDF

Info

Publication number: EP3060220A4
Authority: EP; European Patent Office
Prior art keywords: compositions; oral administration; related compounds; zoledronic acid; treating disease
Prior art date: 2013-10-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP14856165.7A

Other languages

German (de)

English (en)

Other versions

EP3060220A1 (fr

Inventor

Herriot TABUTEAU

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Antecip Bioventures II LLC

Original Assignee

Antecip Bioventures II LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-10-25

Filing date

2014-08-08

Publication date

2017-05-31

2013-10-25 Priority claimed from US14/063,979 external-priority patent/US8802658B2/en

2014-08-08 Application filed by Antecip Bioventures II LLC filed Critical Antecip Bioventures II LLC

2016-08-31 Publication of EP3060220A1 publication Critical patent/EP3060220A1/fr

2017-05-31 Publication of EP3060220A4 publication Critical patent/EP3060220A4/fr

Status Withdrawn legal-status Critical Current

Links

150000001875 compounds Chemical class 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
239000000203 mixture Substances 0.000 title 1
XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 title 1
229960004276 zoledronic acid Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pain & Pain Management (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Rheumatology (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Orthopedic Medicine & Surgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

EP14856165.7A 2013-10-25 2014-08-08 Compositions pour administration orale d'acide zolédronique ou de composés associés pour le traitement de maladies Withdrawn EP3060220A4 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US14/063,979 US8802658B2 (en)	2012-05-14	2013-10-25	Compositions for oral administration of zoledronic acid or related compounds for treating disease
US14/279,241 US20140249317A1 (en)	2012-05-14	2014-05-15	Compositions for oral administration of zoledronic acid or related compounds for treating disease
PCT/US2014/050427 WO2015060924A1 (fr)	2013-10-25	2014-08-08	Compositions pour administration orale d'acide zolédronique ou de composés associés pour le traitement de maladies

Publications (2)

Publication Number	Publication Date
EP3060220A1 EP3060220A1 (fr)	2016-08-31
EP3060220A4 true EP3060220A4 (fr)	2017-05-31

Family

ID=52993341

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP14856165.7A Withdrawn EP3060220A4 (fr)	2013-10-25	2014-08-08	Compositions pour administration orale d'acide zolédronique ou de composés associés pour le traitement de maladies

Country Status (12)

Country	Link
EP (1)	EP3060220A4 (fr)
JP (6)	JP6166471B2 (fr)
KR (3)	KR20190009428A (fr)
CN (2)	CN105960240B (fr)
AU (2)	AU2014340649C1 (fr)
CA (1)	CA2928350C (fr)
HK (1)	HK1257400A1 (fr)
IL (2)	IL245287A0 (fr)
MX (1)	MX2016005396A (fr)
MY (1)	MY176246A (fr)
SG (3)	SG10201609548UA (fr)
WO (1)	WO2015060924A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9956238B2 (en)	2014-05-15	2018-05-01	Antecip Bioventures Ii Llc	Compositions for administration of zoledronic acid or related compounds for treating low back pain
US11654152B2 (en)	2012-05-14	2023-05-23	Antecip Bioventures Ii Llc	Compositions for oral administration of zoledronic acid or related compounds for treating disease
US10463682B2 (en)	2012-05-14	2019-11-05	Antecip Bioventures Ii Llc	Compositions for oral administration of zoledronic acid or related compounds for treating low back pain
US9999629B2 (en)	2012-05-14	2018-06-19	Antecip Bioventures Ii Llc	Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10493085B2 (en)	2012-05-14	2019-12-03	Antecip Bioventures Ii Llc	Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US10413561B2 (en)	2012-05-14	2019-09-17	Antecip Bioventures Ii Llc	Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US10350227B2 (en)	2012-05-14	2019-07-16	Antecip Bioventures Ii Llc	Neridronic acid for treating complex regional pain syndrome
US10016445B2 (en)	2012-05-14	2018-07-10	Antecip Bioventures Ii Llc	Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10413560B2 (en)	2012-05-14	2019-09-17	Antecip Bioventures Ii Llc	Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
SG10201609548UA (en) *	2013-10-25	2016-12-29	Antecip Bioventures Ii Llc	Compositions for oral administration of zoledronic acid or related compounds for treating disease
KR20190045355A (ko)	2016-10-28	2019-05-02	미쯔비시 케미컬 주식회사	탄소섬유용 사이징제, 탄소섬유용 사이징제의 수분산액, 및 사이징제 부착 탄소섬유속
GB202100352D0 (en) *	2021-01-12	2021-02-24	Balticgruppen Bio Ab	New methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002043738A2 (fr) *	2000-11-29	2002-06-06	Novartis Ag	Utilisation de bisphosphonates dans le traitement de la douleur
WO2005005447A2 (fr) *	2003-07-03	2005-01-20	Teva Pharmaceutical Industries Ltd.	Formes cristallines d'acide zoledronique, formes cristallines de sel de sodium de zoledronate, sel de sodium de zoledronate amorphe et procedes de preparation de ceux-ci
WO2013173330A1 (fr) *	2012-05-14	2013-11-21	Antecip Bioventures Ii Llc	Compositions comprenant de l'acide zolédronique ou des composés apparentés permettant de soulager une douleur inflammatoire et des états associés

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6579860B1 (en) *	1998-12-25	2003-06-17	Toray Industries, Inc.	Interleukin-6 production inhibitors
ATE496624T1 (de) *	2001-02-06	2011-02-15	Sydney Children S Hospitals Network Randwick And Westmead Incorporating The Royal Alexandra Hospital	Arzneimittel zur behandlung von osteonekrose und zur versorgung von patienten mit risiko für die entstehung von osteonekrose
CA2443625A1 (fr) *	2001-05-02	2002-11-07	Novartis Ag	Utilisation de bisphosphonates dans le traitement des metastases osseuses associees au cancer de la prostate
US7875597B2 (en) *	2002-07-24	2011-01-25	New York University	Treatment of spinal mechanical pain
CN1705485A (zh) *	2002-10-15	2005-12-07	诺瓦提斯公司	施用双膦酸类化合物的方法
AR046773A1 (es) *	2003-12-23	2005-12-21	Novartis Ag	Formulaciones farmaceuticas de bisfosfonatos
DK2459176T3 (en) *	2009-07-31	2017-12-04	Gruenenthal Gmbh	Crystallization process and bioavailability
WO2011097269A1 (fr) *	2010-02-06	2011-08-11	Thar Pharmaceuticals, Inc.	Procédé de cristallisation et biodisponibilité
US9340565B2 (en) *	2010-11-24	2016-05-17	Thar Pharmaceuticals, Inc.	Crystalline forms
SG10201609548UA (en) *	2013-10-25	2016-12-29	Antecip Bioventures Ii Llc	Compositions for oral administration of zoledronic acid or related compounds for treating disease

2014
- 2014-08-08 SG SG10201609548UA patent/SG10201609548UA/en unknown
- 2014-08-08 MY MYPI2016701480A patent/MY176246A/en unknown
- 2014-08-08 JP JP2016526009A patent/JP6166471B2/ja active Active
- 2014-08-08 WO PCT/US2014/050427 patent/WO2015060924A1/fr not_active Ceased
- 2014-08-08 KR KR1020197001788A patent/KR20190009428A/ko not_active Withdrawn
- 2014-08-08 AU AU2014340649A patent/AU2014340649C1/en active Active
- 2014-08-08 SG SG10201800001VA patent/SG10201800001VA/en unknown
- 2014-08-08 CN CN201480069491.3A patent/CN105960240B/zh active Active
- 2014-08-08 MX MX2016005396A patent/MX2016005396A/es unknown
- 2014-08-08 CA CA2928350A patent/CA2928350C/fr active Active
- 2014-08-08 KR KR1020177013050A patent/KR101975687B1/ko active Active
- 2014-08-08 CN CN201810150156.6A patent/CN108434154A/zh active Pending
- 2014-08-08 EP EP14856165.7A patent/EP3060220A4/fr not_active Withdrawn
- 2014-08-08 KR KR1020167012645A patent/KR101739244B1/ko active Active
- 2014-08-08 SG SG11201603042TA patent/SG11201603042TA/en unknown
2016
- 2016-04-21 IL IL245287A patent/IL245287A0/en unknown
2017
- 2017-02-07 AU AU2017200832A patent/AU2017200832A1/en not_active Abandoned
- 2017-06-22 JP JP2017121884A patent/JP6453387B2/ja active Active
- 2017-08-23 IL IL254123A patent/IL254123A0/en unknown
2018
- 2018-12-12 JP JP2018232467A patent/JP6802245B2/ja active Active
- 2018-12-26 HK HK18116608.0A patent/HK1257400A1/zh unknown
2020
- 2020-11-26 JP JP2020196080A patent/JP7136487B2/ja active Active
2022
- 2022-08-25 JP JP2022134019A patent/JP2022162105A/ja active Pending
2024
- 2024-02-07 JP JP2024017350A patent/JP2024040304A/ja active Pending

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002043738A2 (fr) *	2000-11-29	2002-06-06	Novartis Ag	Utilisation de bisphosphonates dans le traitement de la douleur
WO2005005447A2 (fr) *	2003-07-03	2005-01-20	Teva Pharmaceutical Industries Ltd.	Formes cristallines d'acide zoledronique, formes cristallines de sel de sodium de zoledronate, sel de sodium de zoledronate amorphe et procedes de preparation de ceux-ci
WO2013173330A1 (fr) *	2012-05-14	2013-11-21	Antecip Bioventures Ii Llc	Compositions comprenant de l'acide zolédronique ou des composés apparentés permettant de soulager une douleur inflammatoire et des états associés

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOANNA BIERNACKA ET AL: "PREDICTION OF BIOAVAILABILITY OF SELECTED BISPHOSPHONATES USING IN SILICO METHODS TOWARDS CATEGORIZATION INTO BIOPHARMACEUTICAL CLASSIFICATION SYSTEM", ACTA POLONIAE PHARMACEUTICA - DRUG RESEARCH, vol. 70, no. 5, 1 January 2013 (2013-01-01), PL, pages 877 - 882, XP055365717, ISSN: 0001-6837 *

Also Published As

Publication number	Publication date
JP2019059771A (ja)	2019-04-18
JP6166471B2 (ja)	2017-07-19
CA2928350A1 (fr)	2015-04-30
JP7136487B2 (ja)	2022-09-13
KR101975687B1 (ko)	2019-05-07
AU2017200832A1 (en)	2017-03-02
HK1257400A1 (zh)	2019-10-18
WO2015060924A1 (fr)	2015-04-30
MY176246A (en)	2020-07-24
CA2928350C (fr)	2018-01-09
SG10201800001VA (en)	2018-02-27
KR20170058444A (ko)	2017-05-26
SG10201609548UA (en)	2016-12-29
EP3060220A1 (fr)	2016-08-31
KR101739244B1 (ko)	2017-05-23
JP2017200941A (ja)	2017-11-09
JP2021028343A (ja)	2021-02-25
JP2024040304A (ja)	2024-03-25
JP6802245B2 (ja)	2020-12-16
JP6453387B2 (ja)	2019-01-16
CN105960240A (zh)	2016-09-21
AU2014340649B2 (en)	2016-11-17
KR20160062177A (ko)	2016-06-01
AU2014340649C1 (en)	2017-05-18
SG11201603042TA (en)	2016-05-30
JP2022162105A (ja)	2022-10-21
KR20190009428A (ko)	2019-01-28
CN105960240B (zh)	2018-04-20
IL254123A0 (en)	2017-10-31
JP2016534081A (ja)	2016-11-04
CN108434154A (zh)	2018-08-24
MX2016005396A (es)	2017-03-01
IL245287A0 (en)	2016-06-30

Legal Events

Date	Code	Title	Description
2016-07-29	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2016-08-31	17P	Request for examination filed	Effective date: 20160517
2016-08-31	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2016-08-31	AX	Request for extension of the european patent	Extension state: BA ME
2017-02-01	DAX	Request for extension of the european patent (deleted)
2017-05-31	A4	Supplementary search report drawn up and despatched	Effective date: 20170428
2017-05-31	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 9/20 20060101ALI20170421BHEP Ipc: A61K 31/675 20060101AFI20170421BHEP Ipc: A61P 29/00 20060101ALI20170421BHEP Ipc: A61P 19/02 20060101ALI20170421BHEP
2019-02-07	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2019-03-13	17Q	First examination report despatched	Effective date: 20190211
2020-10-02	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2020-11-04	18D	Application deemed to be withdrawn	Effective date: 20200603

Publication	Publication Date	Title
IL254123A0 (en)	2017-10-31	Preparations for oral administration of zoledronic acid
LT3470063T (lt)	2025-02-10	Farmacinės kompozicijos, skirtos cftr nulemtų ligų gydymui
HUE037154T2 (hu)	2018-08-28	Szubsztituált benzilindazol-származékok mint Bub1 kinázgátlók hiperproliferatív megbetegedések kezelésére
HUE037600T2 (hu)	2018-09-28	Vegyületek és készítmények paraziták által okozott fertõzések kezelésére
EP3180009A4 (fr)	2018-03-14	Formes galéniques d'acide zolédronique pour le traitement de la douleur
HUE054389T2 (hu)	2021-09-28	Eljárás CFTR-mediálta betegségek kezelésére szolgáló gyógyászati kompozíciók elõállítására
EP3030323A4 (fr)	2017-01-11	Inhibiteurs de kdm1a pour le traitement d'une maladie
EP3020401A4 (fr)	2017-02-15	Médicament destiné au traitement de la stéatose hépatique non alcoolique
EP2950809A4 (fr)	2016-09-14	Compositions pharmaceutiques pour le traitement oral du diabète
IL241264A0 (en)	2015-11-30	Compounds and compositions for the treatment of parasitic diseases
EP2961733A4 (fr)	2017-01-18	Composés à base de disulfure pour l'administration d'agents pharmaceutiques
EP3038465A4 (fr)	2017-04-26	Formulation pharmaceutique orale d'omarigliptine
EP3037093A4 (fr)	2017-04-12	Composition contenant un composé monoacétyldiacylglycérol comme principe actif pour la prévention ou le traitement de maladies pulmonaires obstructives chroniques
PT3524260T (pt)	2023-10-13	Composições farmacêuticas para o tratamento de inapetência
EP3318261A4 (fr)	2018-05-09	Utilisation de l'acide zolédronique pour préparer un médicament pour le traitement de la stéatose hépatique
ZA201508452B (en)	2017-02-22	Oral formulation for the treatment of cardiovascular diseases
IL238592B (en)	2018-04-30	Compounds for treatment of liver diseases
EP3021873B8 (fr)	2018-10-24	Composition pur le traitement d'une maladie inflammatoire articulaire
BR112013030930A2 (pt)	2017-08-08	composições farmacêuticas combinadas para o tratamento de tumores
EP3064203A4 (fr)	2017-06-21	Composition pharmaceutique servant à la prévention ou au traitement de maladies hépatiques contenant comme constituant efficace un précurseur de plasmalogène, un plasmalogène ou un analogue de plasmalogène
IL234796B (en)	2018-02-28	Compounds for the treatment of diseases related to ischemia-reperfusion
HUE037176T2 (hu)	2018-08-28	Olaj-alapú gyógyszerészeti készítmény gasztrointesztinális betegségek kezelésére
GB201407847D0 (en)	2014-06-18	Composition for the oral delivery of compounds
IL240119A0 (en)	2015-09-24	Pharmaceutical compositions for oral treatment of diabetes
HUP1100245A2 (en)	2012-11-28	Pharmaceutical composition for the treatment of wounds